Organisation paid for research Program year 2025 Source: CMS Open Payments

The Vancouver Clinic

Neither a doctor nor a teaching hospital

Research payments

$621,062

165 payments

Through program year 2025, The Vancouver Clinic is reported as receiving $621,062 in research payments, across 165 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $86,302 8
2024 Research $74,427 5
2023 Research $56,541 11
2022 Research $74,186 17
2021 Research $127,394 61
2020 Research $79,572 29
2019 Research $122,641 34

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $237,212 78 payments
  2. AstraZeneca Pharmaceuticals LP $181,356 12 payments
  3. Pfizer Inc. $84,247 50 payments
  4. E.R. Squibb & Sons, L.L.C. $43,359 7 payments
  5. AstraZeneca UK Limited $37,827 3 payments
  6. Celgene Corporation $19,599 1 payment
  7. Regeneron Pharmaceuticals, Inc. $12,498 9 payments
  8. GlaxoSmithKline, LLC. $4,500 3 payments
  9. Boston Scientific Corporation $464 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $79,383 29 payments
  2. A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States $76,701 4 payments
  3. The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $71,976 4 payments
  4. M14-431 $64,553 12 payments
  5. M14-234 $52,845 9 payments
  6. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease $40,824 4 payments
  7. a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA $37,827 3 payments
  8. The CHRONICLE Study is a multi center non interventional prospective cohort study of adults with severe asthma who do not achieve control with high dose inhaled corticosteroid ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibody therapy $27,864 3 payments
  9. M14-430 $26,883 16 payments
  10. A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. $21,069 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record